Cited by 166Heart Failure Treatment and ManagementCardiovascular Function and Risk FactorsDiabetes Treatment and Management

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index; 49 of the 65 sources its claims cite were checked for support.

Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial

Open access

Abstract

Patients with obesity-related heart failure with preserved ejection fraction (HFpEF) display circulatory volume expansion and pressure overload contributing to cardiovascular–kidney end-organ damage. In the SUMMIT trial, patients with HFpEF and obesity were randomized to the long-acting glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 receptor agonist tirzepatide ( n = 364, 200 women) or placebo ( n = 367, 193 women). As reported separately, tirzepatide decreased cardiovascular death or worsening heart failure. Here, in this mechanistic secondary analysis of the SUMMIT trial, tirzepatide treatment at 52 weeks, as compared with placebo, reduced systolic blood pressure (estimated treatment difference (ETD) −5 mmHg, 95% confidence interval (CI) −7 to −3; P < 0.001), decreased estimated blood volume (ETD −0.58 l, 95% CI −0.63 to −0.52; P < 0.001) and reduced C-reactive protein levels (ETD −37.2%, 95% CI −45.7 to −27.3; P < 0.001). These changes were coupled with an increase in estimated glomerular filtration rate (ETD 2.90 ml min −1 1.73 m −2 yr −1 , 95% CI 0.94 to 4.86; P = 0.004), a decrease in urine albumin–creatinine ratio (ETD 24 weeks, −25.0%, 95% CI −36 to −13%; P < 0.001; 52 weeks, −15%, 95% CI −28 to 0.1; P = 0.051), a reduction in N-terminal prohormone B-type natriuretic peptide levels (ETD 52 weeks −10.5%, 95% CI −20.7 to 1.0%; P = 0.07) and a reduction in troponin T levels (ETD 52 weeks −10.4%, 95% CI −16.7 to −3.6; P = 0.003). In post hoc exploratory analyses, decreased estimated blood volume with tirzepatide treatment was significantly correlated with decreased blood pressure, reduced microalbuminuria, improved Kansas City Cardiomyopathy Questionnaire Clinical Summary Score and increased 6-min walk distance. Moreover, decreased C-reactive protein levels were correlated with reduced troponin T levels and improved 6-min walk distance. In conclusion, tirzepatide reduced circulatory volume–pressure overload and systemic inflammation and mitigated cardiovascular–kidney end-organ injury in patients with HFpEF and obesity, providing new insights into the mechanisms of benefit from tirzepatide. ClinicalTrials.gov registration: NCT04847557 .

Overview

AI snapshot

Written from the paper’s full text.

TL;DR

In a mechanistic secondary analysis of the SUMMIT trial, tirzepatide reduced circulatory volume–pressure overload and systemic inflammation in patients with obesity-related HFpEF. These changes were accompanied by improved kidney function, reduced albuminuria and myocardial injury, with estimated blood volume reductions correlating with clinical improvement.

Key findings

  • At 52 weeks, tirzepatide versus placebo reduced systolic blood pressure (ETD −4.7 mmHg, 95% CI −6.8 to −2.5; P < 0.001), estimated blood volume (ETD −0.58 l, 95% CI −0.63 to −0.52; P < 0.001), estimated plasma volume (ETD −0.32 l, 95% CI −0.36 to −0.27; P < 0.001) and pulse pressure (ETD −3.9 mmHg, 95% CI −5.6 to −2.2; P < 0.001); diastolic blood pressure effects were not statistically significant.
  • Tirzepatide reduced high-sensitivity CRP at 52 weeks (ETD −37.2%, 95% CI −45.7 to −27.3; P < 0.001), troponin T at 52 weeks (ETD −10.4%, 95% CI −16.7 to −3.6; P = 0.003), and NT-proBNP at 52 weeks (ETD −10.5%, 95% CI −20.7 to 1.0; P = 0.072). Among patients with elevated baseline CRP, normalization occurred in 40.4% with tirzepatide versus 19.4% with placebo (odds ratio 2.90, 95% CI 1.82 to 4.64; P < 0.001).
  • Kidney outcomes: eGFR improved at 52 weeks with tirzepatide versus placebo (ETD 2.9 ml min−1 1.73 m−2, 95% CI 0.9 to 4.9; P = 0.004), and UACR decreased at 24 weeks (ETD −25.0%, 95% CI −35.5 to −12.7; P < 0.001) and 52 weeks (ETD −15.1%, 95% CI −28.0 to 0.1; P = 0.051).
  • In post hoc exploratory analyses, reductions in estimated blood volume with tirzepatide correlated with decreases in systolic blood pressure (slope 6.12, 95% CI 3.47 to 8.78; P < 0.001), decreases in albuminuria (slope 46.7, 95% CI 11.48 to 81.87; P = 0.009), improved KCCQ-CSS (slope −6.287, 95% CI −8.091 to −4.482; P < 0.001) and increased 6-min walk distance (slope −1.175, 95% CI −1.810 to −0.539; P < 0.001). Decreased CRP correlated with reduced troponin T (slope 0.239, 95% CI 0.029 to 0.450; P = 0.026) and improved 6-min walk distance (slope −0.002, 95% CI −0.004 to 0.000; P = 0.016).

Methods

  • Secondary mechanistic analysis of the SUMMIT trial (NCT04847557), a randomized, double-blind, placebo-controlled trial in 731 patients with obesity-related HFpEF: tirzepatide n = 364, placebo n = 367, at 129 centers in 9 countries. Tirzepatide was titrated to 15.0 mg per week subcutaneously as tolerated.
  • Assessed outcomes included blood pressure, estimated blood volume and plasma volume, eGFR, urine albumin–creatinine ratio, high-sensitivity CRP, high-sensitivity troponin T and NT-proBNP at baseline and 12, 24 and 52 weeks. Primary eGFR analysis used cystatin C–based CKD-EPI; sensitivity analyses used creatinine-based and combined creatinine–cystatin C formulas.
  • Main analysis used mixed-effects model repeated measures including treatment, time, treatment-by-time interaction, stratification factors and baseline value; linear and logistic regression explored correlations. Estimated blood volume/plasma volume and regression analyses were post hoc/exploratory; no correction was made for multiple hypothesis testing.

Limitations

  • The paper states that plasma volume was estimated using a weight-based formula (Kaplan–Hakim), so weight loss with tirzepatide would mathematically be expected to reduce estimated plasma volume; the magnitude of blood/plasma volume reduction may therefore be overestimated. Direct indicator-dilution measurement was considered impractical in a large multicenter trial.
  • The paper states that estimated blood volume/plasma volume and the regression analyses were post hoc and exploratory, so these data should be treated as hypothesis-generating; all other outcomes were prespecified. No adjustment was made for multiple hypothesis testing.
  • The paper notes that follow-up for most measures was 52 weeks, limiting conclusions about longer-term effects. It also notes that troponin T can be elevated in skeletal muscle disorders, though such patients were excluded, and that weight loss may reduce skeletal muscle and affect creatinine-based eGFR, which is why cystatin C was used; kidney benefits were consistent across eGFR formulas. Evident from the text: NT-proBNP was only slightly elevated on average and elevated NT-proBNP was not required for eligibility, limiting the ability to detect further reductions.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41591-024-03374-z

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Effects of tirzepatide on pressure overload and volume expansion. a, Least-squares mean changes from baseline in systolic BP (SBP) plotted as a function of duration of treatment in participants randomized to tirzepatide (red circles) or placebo (black squares). b, The estimated mean treatment difference in the change in BV versus baseline with tirzepatide (TZP) compared with placebo plotted as a function of duration of treatment. The error bars represent s.e.m. for both panels; two-sided P < 0.001 for each time point comparison for a and b based upon comparing the least-squares means calculated from a mixed-model repeated-measures model incorporating baseline value, sex, history of HF decompensation within 12 months, diabetes status, baseline BMI group (<35, ≥35 kg m−2), treatment assignment, time, and treatment × time interaction. No correction was made for multiple hypothesis testing.
Fig. 1 Effects of tirzepatide on pressure overload and volume expansion. a, Least-squares mean changes from baseline in systolic BP (SBP) plotted as a function of duration of treatment in participants randomized to tirzepatide (red circles) or placebo (black squares). b, The estimated mean treatment difference in the change in BV versus baseline with tirzepatide (TZP) compared with placebo plotted as a function of duration of treatment. The error bars represent s.e.m. for both panels; two-sided P < 0.001 for each time point comparison for a and b based upon comparing the least-squares means calculated from a mixed-model repeated-measures model incorporating baseline value, sex, history of HF decompensation within 12 months, diabetes status, baseline BMI group (<35, ≥35 kg m−2), treatment assignment, time, and treatment × time interaction. No correction was made for multiple hypothesis testing.CC BY · PubMed Central
Fig. 2 Effects of tirzepatide on systemic inflammation, cardiac injury and natriuretic peptide levels. a, Least-squares mean changes from baseline in CRP plotted as a function of duration of treatment in participants randomized to tirzepatide (red circles) or placebo (black squares). b, The estimated mean treatment difference in the change in troponin T and NT-proBNP with tirzepatide (TZP) to baseline compared with placebo plotted as a function of duration of treatment. The error bars represent the s.e.m. for all panels; P values are two-sided for each time point comparison for a and b based upon comparing the least-squares means calculated from a mixed-model repeated-measures model incorporating baseline value, history of HF decompensation within 12 months, diabetes status, baseline BMI group (<35, ≥35 kg m−2), treatment assignment, time, and treatment × time interaction. No correction was made for multiple hypothesis testing.
Fig. 2 Effects of tirzepatide on systemic inflammation, cardiac injury and natriuretic peptide levels. a, Least-squares mean changes from baseline in CRP plotted as a function of duration of treatment in participants randomized to tirzepatide (red circles) or placebo (black squares). b, The estimated mean treatment difference in the change in troponin T and NT-proBNP with tirzepatide (TZP) to baseline compared with placebo plotted as a function of duration of treatment. The error bars represent the s.e.m. for all panels; P values are two-sided for each time point comparison for a and b based upon comparing the least-squares means calculated from a mixed-model repeated-measures model incorporating baseline value, history of HF decompensation within 12 months, diabetes status, baseline BMI group (<35, ≥35 kg m−2), treatment assignment, time, and treatment × time interaction. No correction was made for multiple hypothesis testing.CC BY · PubMed Central
Fig. 3 Effects of tirzepatide on kidney function and albuminuria. a, Top: least-squares mean changes from baseline in eGFR plotted as a function of duration of treatment in participants randomized to tirzepatide (red circles) or placebo (black squares). Bottom: the estimated mean treatment difference in the change in eGFR with tirzepatide versus baseline compared with placebo plotted as a function of duration of treatment. b, The least-squares mean change in UACR in participants treated with tirzepatide (red) and placebo (black) as a function of duration of treatment. The error bars represent the s.e.m. for all panels; P values are two-sided for each time point comparison for a and b based upon comparing the least-squares means calculated from a mixed-model repeated-measures model incorporating baseline value, sex, history of HF decompensation within 12 months, diabetes status, baseline BMI group (<35, ≥35 kg m−2), treatment assignment, time, and treatment × time interaction. No correction was made for multiple hypothesis testing.
Fig. 3 Effects of tirzepatide on kidney function and albuminuria. a, Top: least-squares mean changes from baseline in eGFR plotted as a function of duration of treatment in participants randomized to tirzepatide (red circles) or placebo (black squares). Bottom: the estimated mean treatment difference in the change in eGFR with tirzepatide versus baseline compared with placebo plotted as a function of duration of treatment. b, The least-squares mean change in UACR in participants treated with tirzepatide (red) and placebo (black) as a function of duration of treatment. The error bars represent the s.e.m. for all panels; P values are two-sided for each time point comparison for a and b based upon comparing the least-squares means calculated from a mixed-model repeated-measures model incorporating baseline value, sex, history of HF decompensation within 12 months, diabetes status, baseline BMI group (<35, ≥35 kg m−2), treatment assignment, time, and treatment × time interaction. No correction was made for multiple hypothesis testing.CC BY · PubMed Central

Verification

Claims the paper makes

78 Own result · 21 Partly supported · 18 Own interpretation · 14 Own method · 9 Supported · 5 Sources not found · 3 No basis given · 2 No full text of the sources · 2 Not checked yet · 1 Supported so far · 1 Couldn’t confirm · accuracy not yet measured

Verify all 2 references — free account

Show all 97 claims

  • It may state two separate claims as one. 37
  • Probably not a substantial claim. 32
57 of 57
  • The paper relies on this without support.

    The mechanisms underlying the favorable effects of tirzepatide in obesity-related HFpEF remain unclear.

    “The mechanisms underlying these favorable effects of tirzepatide remain unclear.”
  • The paper relies on this without support.

    The mechanisms underlying clinical improvement with incretins such as tirzepatide and semaglutide in patients with obesity-related HFpEF have remained unclear.

    “but the mechanisms underlying clinical improvement with incretins such as tirzepatide and semaglutide in patients with obesity-related HFpEF have remained unclear.”
2 of 2

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 43 references

Cited by

Sorted by citations

Metadata

Authors
Borlaug, B. A., Zile, M. R., Kramer, C. M., Baum, S. J., Hurt, K., Litwin, S. E., Murakami, M., Ou, Y., Upadhyay, N., & Packer, M.
Affiliations
  • Mayo Clinic (US)
  • Medical University of South Carolina (US)
  • University of Virginia Health System (US)
  • Eli Lilly (United States) (US)
  • Baylor University Medical Center (US)
Corresponding author
Borlaug, Barry A.
Venue
Nature Medicine
Published
2024-11-17
Volume
31
Issue
2
Pages
544-551
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4404448817
Cited by
166
References
43
Citations by year
2026: 83 · 2025: 81 · 2024: 2
FWCI
46.66
Type
journal article
Language
en
Open access
Locations
  • Nature Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Eli Lilly and Company
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
tirzepatide, heart failure with preserved ejection fraction, obesity, circulatory overload, blood volume, blood pressure, C-reactive protein, glomerular filtration rate, albuminuria, natriuretic peptides, troponin T, SUMMIT trial, GIP/GLP-1 receptor agonist
MeSH terms
Tirzepatide, Aged, Blood Pressure, C-Reactive Protein, Female, Heart Failure, Humans, Male, Middle Aged, Obesity, Peptide Fragments, Stroke Volume, Natriuretic Peptide, Brain

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review